Apollomics Company Leadership
| APLM Stock | 19.30 0.60 3.21% |
Apollomics employs about 13 people. The company is managed by 10 executives with a total tenure of roughly 31 years, averaging almost 3.0 years of service per executive, having 1.3 employees per reported executive. Analysis of Apollomics' management performance can provide insight into the firm performance.
Apollomics | Build AI portfolio with Apollomics Stock |
Apollomics Management Team Effectiveness
The company has return on total asset (ROA) of (0.7507) % which means that it has lost $0.7507 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.3367) %, meaning that it created substantial loss on money invested by shareholders. Apollomics' management efficiency ratios could be used to measure how well Apollomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of January 2026, Return On Tangible Assets is likely to grow to -5.18. In addition to that, Return On Capital Employed is likely to grow to -8.08. As of the 3rd of January 2026, Total Assets is likely to drop to about 11.2 M. In addition to that, Non Current Assets Total is likely to drop to about 2.4 MAs of the 3rd of January 2026, Common Stock Shares Outstanding is likely to drop to about 685.6 KThe market capitalization of Apollomics Class A is USD44.92 Million. Almost 99.33 percent of Apollomics outstanding shares are held by general public with 0.67 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Shares in Circulation | First Issued 2019-06-30 | Previous Quarter 1.1 M | Current Value 1.1 M | Avarage Shares Outstanding 1.3 M | Quarterly Volatility 1.2 M |
Apollomics Workforce Comparison
Apollomics Class A is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 832. Apollomics claims roughly 13.0 in number of employees contributing just under 2% to equities under Health Care industry.
Apollomics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apollomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apollomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Apollomics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yungfong Song over a year ago Conversion by Yungfong Song of 2482500 shares of Apollomics |
Apollomics Notable Stakeholders
An Apollomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Apollomics often face trade-offs trying to please all of them. Apollomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Apollomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| HungWen Chen | CEO Board | Profile | |
| GuoLiang Yu | CEO CoFounder | Profile | |
| Sanjeev MBA | President CoFounder | Profile | |
| Chen Jan | COO Director | Profile | |
| YiKuei Chen | Director COO | Profile | |
| Matthew Plunkett | Chief Officer | Profile | |
| MBA CAIA | Chief Officer | Profile | |
| Chinglin Lai | Senior Management | Profile | |
| KinHung MD | Chief Officer | Profile | |
| Lijuan Wang | Chief China | Profile |
About Apollomics Management Performance
The success or failure of an entity such as Apollomics Class A often depends on how effective the management is. Apollomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Apollomics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Apollomics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.45) | (5.18) | |
| Return On Capital Employed | (8.50) | (8.08) | |
| Return On Assets | (4.73) | (4.49) | |
| Return On Equity | (12.73) | (12.10) |
Apollomics Workforce Analysis
Traditionally, organizations such as Apollomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Apollomics within its industry.Apollomics Manpower Efficiency
Return on Apollomics Manpower
| Revenue Per Employee | 15.2K | |
| Revenue Per Executive | 19.8K | |
| Net Loss Per Employee | 4.1M | |
| Net Loss Per Executive | 5.4M | |
| Working Capital Per Employee | 220.6K | |
| Working Capital Per Executive | 286.8K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apollomics Class A. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.